Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a Research & Development (R&D) Day to discuss its emerging pipeline of RNAi therapeutics that leverage its proprietary Targeted RNAi Molecule (TRIMTM) platform on October 16, 2018 in New York City.

Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics

Pasadena. CA | Posted on September 25th, 2018

The R&D Day will feature presentations by Ira Goldberg, M.D. (NYU Langone Medical Center) who will discuss the current treatment landscape and unmet medical need for patients with dyslipidemia and hypertriglyceridemia.

Arrowhead's management team will provide an overview of the company’s pipeline of RNAi-based therapeutics. Discussion topics will include:

ARO-APOC3 for patients with hypertriglyceridemia. A CTA filing is planned by the end of 2018.
ARO-ANG3 for patients with dyslipidemia. A CTA filing is planned by the end of 2018.
ARO-ENaC for patients with cystic fibrosis. A CTA filing is planned in 2019.
ARO-HIF2 for patients with renal cell carcinoma. A CTA filing is planned in 2019.
This event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited. To reserve a seat, please click here to register.

A live and archived webcast of the event, with slides, may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts .

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400

or
Investors and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Elliot Scientific now representing Raman Imaging specialists WITec in the UK and Eire - Unique correlative analysis in one instrument: Raman/AFM, Raman/SNOM December 10th, 2018

A new 'spin' on kagome lattices: Team's findings shed new light on the presence of spin-orbit coupling and topological spin textures in kagome lattices December 9th, 2018

Milestone for bERLinPro: Photocathodes with high quantum efficiency December 8th, 2018

Harnessing the power of 'spin orbit' coupling in silicon: Scaling up quantum computation December 7th, 2018

Possible Futures

A new 'spin' on kagome lattices: Team's findings shed new light on the presence of spin-orbit coupling and topological spin textures in kagome lattices December 9th, 2018

Milestone for bERLinPro: Photocathodes with high quantum efficiency December 8th, 2018

Harnessing the power of 'spin orbit' coupling in silicon: Scaling up quantum computation December 7th, 2018

CEA-Leti’s RRAM-based TCAM Circuits Meet Requirements of Multicore Neuromorphic Processors December 5th, 2018

Nanomedicine

A*STAR, One BioMed launch S$9m joint lab to make diagnostic kit for infectious diseases December 3rd, 2018

New research could fine-tune the gene scissors CRISPR December 1st, 2018

It's not a shock: Better bandage promotes powerful healing November 29th, 2018

Arrowhead Pharmaceuticals to Webcast 2018 Fiscal Year End Results November 27th, 2018

Announcements

Elliot Scientific now representing Raman Imaging specialists WITec in the UK and Eire - Unique correlative analysis in one instrument: Raman/AFM, Raman/SNOM December 10th, 2018

A new 'spin' on kagome lattices: Team's findings shed new light on the presence of spin-orbit coupling and topological spin textures in kagome lattices December 9th, 2018

Milestone for bERLinPro: Photocathodes with high quantum efficiency December 8th, 2018

Harnessing the power of 'spin orbit' coupling in silicon: Scaling up quantum computation December 7th, 2018

Events/Classes

CEA-Leti’s RRAM-based TCAM Circuits Meet Requirements of Multicore Neuromorphic Processors December 5th, 2018

CEA-Leti Moves 3D Sequential Integration Closer to Commercialization: Paper Presented at IEDM 2018 Describes Breakthroughs in Six Process Steps December 3rd, 2018

Arrowhead Pharmaceuticals to Webcast 2018 Fiscal Year End Results November 27th, 2018

Bosch provides customized IoT and Industry 4.0 solutions: Bosch Mondeville and Bosch Connected Devices and Solutions collaborate to meet a wide variety of customer requirements November 16th, 2018

Nanobiotechnology

A*STAR, One BioMed launch S$9m joint lab to make diagnostic kit for infectious diseases December 3rd, 2018

New research could fine-tune the gene scissors CRISPR December 1st, 2018

Arrowhead Pharmaceuticals to Webcast 2018 Fiscal Year End Results November 27th, 2018

How low can we go? Nanopore detection of single flu viruses to control outbreaks: Osaka University-led study shows that label-free digital diagnostics based on nanopore analytics and AI technology can characterize individual virions by their distinct physical features November 23rd, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project